Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

349 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma.
Zamboni WC, Gervais AC, Egorin MJ, Schellens JH, Zuhowski EG, Pluim D, Joseph E, Hamburger DR, Working PK, Colbern G, Tonda ME, Potter DM, Eiseman JL. Zamboni WC, et al. Among authors: egorin mj. Cancer Chemother Pharmacol. 2004 Apr;53(4):329-36. doi: 10.1007/s00280-003-0719-4. Epub 2003 Dec 12. Cancer Chemother Pharmacol. 2004. PMID: 14673619
Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors.
Jung LL, Ramanathan RK, Egorin MJ, Jin R, Belani CP, Potter DM, Strychor S, Trump DL, Walko C, Fakih M, Zamboni WC. Jung LL, et al. Among authors: egorin mj. Cancer Chemother Pharmacol. 2004 Dec;54(6):487-96. doi: 10.1007/s00280-004-0835-9. Epub 2004 Aug 18. Cancer Chemother Pharmacol. 2004. PMID: 15322760 Clinical Trial.
Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts.
Eiseman JL, Lan J, Lagattuta TF, Hamburger DR, Joseph E, Covey JM, Egorin MJ. Eiseman JL, et al. Among authors: egorin mj. Cancer Chemother Pharmacol. 2005 Jan;55(1):21-32. doi: 10.1007/s00280-004-0865-3. Epub 2004 Aug 27. Cancer Chemother Pharmacol. 2005. PMID: 15338192
Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers.
Ramanathan RK, Fakih M, Mani S, Deutsch M, Perez RP, Ritter MA, Eiseman JL, Ivy SP, Trump DL, Belani CP, Parise RA, Potter DM, Egorin MJ. Ramanathan RK, et al. Among authors: egorin mj. Cancer Chemother Pharmacol. 2006 Apr;57(4):465-74. doi: 10.1007/s00280-005-0071-y. Epub 2005 Aug 25. Cancer Chemother Pharmacol. 2006. PMID: 16133531 Clinical Trial.
Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors.
Zamboni WC, Goel S, Iqbal T, Parise RA, Strychor S, Repinski TV, Egorin MJ, Mani S. Zamboni WC, et al. Among authors: egorin mj. Cancer Chemother Pharmacol. 2006 May;57(5):631-9. doi: 10.1007/s00280-005-0084-6. Epub 2005 Oct 5. Cancer Chemother Pharmacol. 2006. PMID: 16205924 Clinical Trial.
349 results